Justification

Gemeinsamer Bundesausschuss

to the Resolution of the Federal Joint Committee (G-BA) on the Initiation of a Renewed Benefit Assessment According to Section 35a, Paragraph 1, SGB V in Conjunction with Section 3, Paragraph 1, No. 4 of the Ordinance on the Benefit Assessment of Pharmaceuticals (AM-NutzenV) and Chapter 5, Section 13 of the Rules of Procedure of the G-BA (VerfO): Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Canagliflozine and Canagliflozine/Metformin

of 16 April 2020

Contents

1. Legal basis

According to Section 35a, paragraph 1 German Social Code, Book Five (SGB V), the Federal Joint Committee (G-BA) assesses the benefit of reimbursable medicinal products with new active ingredients. This includes in particular the assessment of the additional benefit and its therapeutic significance. The benefit assessment is carried out on the basis of evidence provided by the pharmaceutical company, which must be submitted to the G-BA electronically, including all clinical trials the pharmaceutical company has conducted or commissioned, at the latest at the time of the first placing on the market as well as the marketing authorisation of new therapeutic indications of the medicinal product, and which must contain the following information in particular:

1. Approved therapeutic indications,
2. Medical benefit,
3. Additional medical benefit in relation to the appropriate comparator therapy,
4. Number of patients and patient groups for whom there is a therapeutically significant additional benefit,
5. Treatment costs for statutory health insurance funds,
6. Requirements for a quality-assured application.

According to Section 35a, paragraph 1, SGB V in conjunction with Section 3, paragraph 1, No. 4 AM-NutzenV and Chapter 5, Section 13 VerfO, the G-BA may, at the request of its members or of the organisations and institutions mentioned in Section 139b, paragraph 1, sentence 2 SGB V, initiate a new benefit assessment according to Section 35a SGB V at the earliest one year after publication of the resolution according to Chapter 5, Section 20 VerfO because of new scientific findings (Section 13, paragraph 1, sentence 1 VerfO).

2. Key points of the decision

Canagliflozine as the active ingredient of the medicinal product Invokana® or the fixed medicinal product combination Vokanamet® was first placed on the (German) market on 15 March 2014 and 15 August 2014, respectively. At its session on 4 September 2014 (canagliflozine) and 5 February 2015 (canagliflozine/metformin), the G-BA passed a resolution on the benefit assessment of canagliflozine and canagliflozine/metformin according to Section 35a SGB V.

In the justification to the resolutions of 4 September 2014 and 5 February 2015, it was stated that no valid conclusions on the additional benefit and safety profile of canagliflozine or canagliflozine/metformin could be drawn because of methodological deficiencies in the studies submitted. Long-term data on overall survival, cardiovascular safety, and general safety profile for canagliflozine and canagliflozin/metformin were not available when the resolutions were adopted on 4 September 2014 (canagliflozine) and 5 February 2015 (canagliflozin/metformin).

However, because of the chronic course of type 2 diabetes mellitus and the resulting long-term treatment of patients, these are urgently required[1].

The justification for a renewed benefit assessment for the active ingredient canagliflozine and the active ingredient combination canagliflozine/metformin is that the data of the completed CANVAS (NCT01032629) and CANVAS-R (NCT 01989754)[2] Phase III and IV studies are to be considered new scientific findings that constitute the facts of a renewed benefit assessment to be initiated ex officio by the G-BA based on new scientific findings in accordance with Section 35a, paragraph 1 SGB V in conjunction with Section 3, paragraph 1, No. 4 AM-NutzenV and Chapter 5, Section 13, paragraph 1, sentence 2 VerfO. Because of the duration and size of the studies (approx. 10,142 adult patients with type 2 diabetes mellitus) and the survey of patient-relevant cardiovascular or renal or endpoints as well as pending safety data, the studies are considered relevant for a renewed benefit assessment because of new scientific findings.

In accordance with Chapter 5, Section 13, paragraph 1, sentence 3 in conjunction with Section 16, paragraph 2 VerfO, the dossier for the benefit assessment for canagliflozine or canagliflozine/metformin must be submitted within three months of notification of the resolution by the G-BA. The date of notification shall be 1 August 2020. Based on this date, the dossier shall be submitted by 2 November 2020 at the latest. If Invokana® or Vokanamet® is not available on the German market at that time, the dossier shall be submitted no later than the date on which Invokana® or Vokanamet® is placed on the market in Germany.

The G-BA hereby offers the pharmaceutical company concerned consultation according to Chapter 5, Section 7 VerfO.

3. Bureaucratic costs

The proposed resolution does not create any new or amended information obligations for care providers within the meaning of Annex II to Chapter 1 VerfO and, accordingly, no bureaucratic costs.

[1] Justification to the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL) Annex XII – Resolutions on the Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V – Canagliflozine of 4 September 2014 and Canagliflozine/Metformin of 5 February 2015, available at https://www.g-ba.de/downloads/40-268-2937/2014-09-04_AM-RL-XII_Canagliflozin_2014-03-15-D-101_TrG.pdf and https://www.g-ba.de/downloads/40-268-3099/2015-02-05_AM-RL-XII_CanagliflozinMetformin_2014-08-15-D-124_TrG.pdf

[2] Canagliflozine for Primary and Secondary Prevention of Cardiovascular Events. Results From the CANVAS Program (Canagliflozine Cardiovascular Assessment Study) https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.117.032038?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

4. Process sequence

The matter was discussed in the Working Group Section 35a on 17 March 2020 and in the Subcommittee on Medicinal Products on 7 April 2020, and a corresponding resolution recommendation was prepared for the plenum.

At its session on 16 April 2020, the plenum decided to initiate a renewed benefit assessment according to Section 35a SGB V.

Berlin, 16 April 2020

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Prof. Hecken